Daewoong pharmaceutical Co.,Ltd (069620.KS)
KRW 125500.0
(-2.64%)
KRW 125500.0
(-2.64%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 858.02 Billion KRW | 4.37% |
| 2022 | 822.11 Billion KRW | 15.34% |
| 2021 | 712.77 Billion KRW | 6.12% |
| 2020 | 671.65 Billion KRW | 10.15% |
| 2019 | 609.74 Billion KRW | 1.62% |
| 2018 | 600.03 Billion KRW | 3.1% |
| 2017 | 581.98 Billion KRW | 7.75% |
| 2016 | 540.14 Billion KRW | 48.28% |
| 2015 | 364.28 Billion KRW | 52.58% |
| 2014 | 238.75 Billion KRW | 69.27% |
| 2013 | 141.04 Billion KRW | 47.3% |
| 2012 | 95.75 Billion KRW | -29.61% |
| 2011 | 136.04 Billion KRW | -26.93% |
| 2010 | 186.19 Billion KRW | 2.15% |
| 2009 | 182.28 Billion KRW | -12.11% |
| 2008 | 207.39 Billion KRW | 68.28% |
| 2007 | 123.24 Billion KRW | 12.7% |
| 2006 | 109.35 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 876.68 Billion KRW | 2.17% |
| 2024 Q2 | 970.95 Billion KRW | 10.75% |
| 2023 Q4 | 858.02 Billion KRW | 0.49% |
| 2023 FY | 858.02 Billion KRW | 4.37% |
| 2023 Q2 | 821.07 Billion KRW | -3.26% |
| 2023 Q1 | 848.78 Billion KRW | 3.24% |
| 2023 Q3 | 853.87 Billion KRW | 3.99% |
| 2022 FY | 822.11 Billion KRW | 15.34% |
| 2022 Q3 | 782.77 Billion KRW | 3.06% |
| 2022 Q4 | 822.11 Billion KRW | 5.03% |
| 2022 Q2 | 759.51 Billion KRW | 2.43% |
| 2022 Q1 | 741.48 Billion KRW | 4.03% |
| 2021 Q2 | 718.49 Billion KRW | -1.84% |
| 2021 FY | 712.77 Billion KRW | 6.12% |
| 2021 Q1 | 731.97 Billion KRW | 8.98% |
| 2021 Q3 | 726.8 Billion KRW | 1.16% |
| 2021 Q4 | 712.77 Billion KRW | -1.93% |
| 2020 Q2 | 594.66 Billion KRW | -2.63% |
| 2020 Q1 | 610.7 Billion KRW | 0.16% |
| 2020 FY | 671.65 Billion KRW | 10.15% |
| 2020 Q3 | 671.27 Billion KRW | 12.88% |
| 2020 Q4 | 671.65 Billion KRW | 0.06% |
| 2019 Q2 | 610.9 Billion KRW | 1.07% |
| 2019 FY | 609.74 Billion KRW | 1.62% |
| 2019 Q1 | 604.46 Billion KRW | 0.74% |
| 2019 Q4 | 609.74 Billion KRW | -1.25% |
| 2019 Q3 | 617.48 Billion KRW | 1.08% |
| 2018 Q3 | 585.58 Billion KRW | -0.34% |
| 2018 Q1 | 585.57 Billion KRW | 0.62% |
| 2018 FY | 600.03 Billion KRW | 3.1% |
| 2018 Q4 | 600.03 Billion KRW | 2.47% |
| 2018 Q2 | 587.57 Billion KRW | 0.34% |
| 2017 Q4 | 581.98 Billion KRW | 3.53% |
| 2017 FY | 581.98 Billion KRW | 7.75% |
| 2017 Q3 | 562.16 Billion KRW | 2.67% |
| 2017 Q2 | 547.53 Billion KRW | 0.88% |
| 2017 Q1 | 542.76 Billion KRW | 0.48% |
| 2016 Q4 | 540.14 Billion KRW | 11.48% |
| 2016 Q1 | 369.86 Billion KRW | 1.53% |
| 2016 Q2 | 489.54 Billion KRW | 32.36% |
| 2016 FY | 540.14 Billion KRW | 48.28% |
| 2016 Q3 | 484.51 Billion KRW | -1.03% |
| 2015 FY | 364.28 Billion KRW | 52.58% |
| 2015 Q2 | 261.3 Billion KRW | 2.65% |
| 2015 Q3 | 382.11 Billion KRW | 46.23% |
| 2015 Q1 | 254.55 Billion KRW | 6.62% |
| 2015 Q4 | 364.28 Billion KRW | -4.66% |
| 2014 Q2 | 134.51 Billion KRW | -4.9% |
| 2014 Q3 | 160.4 Billion KRW | 19.25% |
| 2014 FY | 238.75 Billion KRW | 69.27% |
| 2014 Q4 | 238.75 Billion KRW | 48.84% |
| 2014 Q1 | 141.44 Billion KRW | 0.28% |
| 2013 FY | 141.04 Billion KRW | 47.3% |
| 2013 Q3 | 100.18 Billion KRW | 1.11% |
| 2013 Q2 | 99.08 Billion KRW | -15.29% |
| 2013 Q4 | 141.04 Billion KRW | 40.79% |
| 2013 Q1 | 116.96 Billion KRW | 22.15% |
| 2012 Q1 | 124.53 Billion KRW | 0.0% |
| 2012 Q4 | 95.75 Billion KRW | 0.0% |
| 2012 FY | 95.75 Billion KRW | -29.61% |
| 2011 Q1 | 166.17 Billion KRW | 0.0% |
| 2011 FY | 136.04 Billion KRW | -26.93% |
| 2011 Q3 | 142.26 Billion KRW | -10.27% |
| 2011 Q2 | 158.54 Billion KRW | -4.59% |
| 2010 Q1 | 182.28 Billion KRW | 6.46% |
| 2010 FY | 186.19 Billion KRW | 2.15% |
| 2010 Q2 | 222.66 Billion KRW | 22.15% |
| 2010 Q3 | 184.18 Billion KRW | -17.28% |
| 2009 Q2 | 196.78 Billion KRW | 0.0% |
| 2009 Q4 | 171.21 Billion KRW | -0.67% |
| 2009 Q3 | 172.36 Billion KRW | -12.41% |
| 2009 FY | 182.28 Billion KRW | -12.11% |
| 2008 Q3 | 190.84 Billion KRW | 29.33% |
| 2008 Q2 | 147.56 Billion KRW | 0.0% |
| 2008 Q4 | 215.61 Billion KRW | 12.98% |
| 2008 FY | 207.39 Billion KRW | 68.28% |
| 2007 FY | 123.24 Billion KRW | 12.7% |
| 2007 Q2 | 107.95 Billion KRW | 0.0% |
| 2007 Q4 | 103.06 Billion KRW | 0.59% |
| 2007 Q3 | 102.45 Billion KRW | -5.09% |
| 2006 FY | 109.35 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -1002.046% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 7.719% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | -21.345% |
| HANDOK Inc. | 449.7 Billion KRW | -90.798% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -901.548% |
| Yuhan Corporation | 712.33 Billion KRW | -20.453% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | -35.783% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -5298.286% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | -0.728% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -1502.936% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -316.771% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -1041.438% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -480.557% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -1118.77% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -1002.046% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -2254.879% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | -241.639% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -288.767% |
| JW Holdings Corporation | 827.51 Billion KRW | -3.688% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | -96.348% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | -46.224% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -126.036% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -981.984% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -1126.324% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -253.313% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | -159.777% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -1002.046% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | -75.102% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -126.036% |
| Yuhan Corporation | 712.33 Billion KRW | -20.453% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | -79.575% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -526.443% |
| Suheung Co., Ltd. | 516.66 Billion KRW | -66.07% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -126.036% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -455.229% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -853.734% |
| CKD Bio Corp. | 170.76 Billion KRW | -402.475% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -252.036% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -444.239% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -1894.53% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -981.984% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | -35.653% |
| Boryung Corporation | 373.1 Billion KRW | -129.968% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -312.123% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -316.771% |
| JW Lifescience Corporation | 96.44 Billion KRW | -789.673% |